Dermatan sulfate
Oligosaccharide in Homo sapiens that 4 drugs act on.
- Drugs that act on it: 4
- Approved: 2
- In phases 1 to 3: 2
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 4
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- BioMarin Pharmaceutical250%
- Green Cross125%
- JCR Pharmaceuticals Co., Ltd.125%
| LaronidaseBoxed warning | Approved | BioMarin Pharmaceutical | Protein or peptide | Hydrolytic enzyme | 2 |
| GalsulfaseBoxed warning | Approved | BioMarin Pharmaceutical | Protein or peptide | Hydrolytic enzyme | 1 |
| Idursulfase beta | Phase 3 | Green Cross | Protein or peptide | Hydrolytic enzyme | 0 |
| Pabinafusp alfa | Phase 3 | JCR Pharmaceuticals Co., Ltd. | Protein or peptide | Hydrolytic enzyme | 0 |
| Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH. | Laronidase | — | Active, not recruiting | Masonic Cancer Center, University of Minnesota | Dec 2, 2022 |
| PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders) | Galsulfase, Laronidase | Phase 1 | Recruiting | University of California, San Francisco | Aug 31, 2020 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364179, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets